Prof Gareth Morgan sits down with Dr Xavier Leleu to discuss developments on a trial that examines treatment with pomalidomide.  Dr Leleu notes that treatment with pomalidomide would be effective advance myeloma as more and more patients are exposed to other treatments and develop resistance.

The aim of Dr Leleu’s is to find the optimal design for treatment with pomalidomide, finding the safest schedule and the most active.  Basic results have been no difference between the two arms of the study, but both arms had an increase in long term response.  Dr Leleu discusses the benefits of methods of administering pomalidomide and future research taking place.

This programme was made possible with an educational grant provided by CELGENE.